



CYCLOPOSPHAMIDE Prednisolone

INDICATION (ICD10) C49

1. Metastatic soft tissue sarcoma for patients with poor prognosis and elderly with comprehensive geriatric assessment (CGA) tool.

REGIMEN

Days 1 to 7 CYCLOPHOSPHAMIDE 100mg PO twice daily Prednisolone 20mg PO once daily

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 14 days until progression

ADMINISTRATION

Cyclophosphamide is available as 50mg tablets.

ANTI-EMETICS

Low risk days 1 to 7

CONCURRENT MEDICATION REQUIRED

None required

EXTRAVASATION AND TYPE OF LINE / FILTERS

Not applicable

INVESTIGATIONS

Blood results required before SACT administration FBC, U&E and LFTs days 1 and 14, then monthly Neutrophils x $10^9/L \ge 1.5$ Platelets x $10^9/L \ge 100$

MAIN TOXICITES AND ADVERSE REACTIONS

Cyclophosphamide	may irritate bladder, drink copious volumes of water.
Prednisolone	Steroid effects – monitors BMs

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

Cyclophosphamide	Cytochrome P450 enzyme inducers (e.g. rifampicin, carbamazepine, phenytoin, St Johns Wort, corticosteroids): may increase active
	cyclophosphamide metabolites.
	Allopurinol, Cimetidine and protease inhibitors: may increase active
	metabolites.
	Aprepitant, Ciprofloxacin, Fluconazole, Itraconazole: may reduce
	activation of cyclophosphamide and alter the effectiveness of treatment.
	Grapefruit juice: decreased or delayed activation of cyclophosphamide.
	Patients should be advised to avoid grapefruit juice.





DOSE MODIFICATIONS

Renal impairment

Cyclophosphamide CrCl 10-29ml/min Consider giving 75% dose

REFERENCES

1. European Jounal of Cancer vol 47 issue 4 pg 515-519 March 2011